Re: Prospectus dtd 5/30/96
                                                                File No. 333-719
                                                                Rule 424 (b) (1)

PROSPECTUS

                                    451,000 SHARES

                                BASE TEN SYSTEMS, INC.

                                 CLASS A COMMON STOCK

    All 451,000 shares (the "Shares") of Class A Common Stock ("Class A Common
Stock"), of Base Ten Systems, Inc., a New Jersey corporation (the "Company" or
"Base Ten"), offered hereby are being offered by certain stockholders of the
Company (the "Selling Stockholders").  The Shares may be offered by the Selling
Stockholders from time to time in open market transactions, negotiated
transactions, principal transactions or by a combination of these methods of
sale.  See "Plan of Distribution."

    The Shares offered for sale hereby are issuable to the Selling Stockholders
upon exercise of outstanding warrants and options.  The Company has agreed to
provide certain registration rights to the Selling Stockholders.  See "Selling
Stockholders."

    None of the proceeds from the sale of the Shares by the Selling
Stockholders will be received by the Company.  Base Ten has agreed to bear all
expenses in connection with the registration and sales of the Shares, other than
underwriting discounts and selling commissions.  The Company has also agreed to
indemnify the Selling Stockholders against certain liabilities, including
liabilities under the Securities Act of 1933, as amended.

    On May 30, 1996, the last reported sale price of the Class A Common Stock
on the Nasdaq National Market was $ 12 5/8.  The Class A Common Stock is traded
under the Nasdaq symbol "BASEA."

    See "RISK FACTORS" on page 2 for a discussion of certain factors that
should be considered in evaluating an investment in the Common Stock.


- --------------------------------------------------------------------------------
  THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND
 EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE SECURITIES
   AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED UPON THE
 ACCURACY OR ADEQUACY OF THIS PROSPECTUS.  ANY REPRESENTATION TO THE CONTRARY IS
                              A CRIMINAL OFFENSE.
- --------------------------------------------------------------------------------

MAY 30, 1996



                                AVAILABLE INFORMATION

    The Company  is subject to the informational requirements of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), and in accordance
therewith files reports and other information with the Securities and Exchange
Commission (the "SEC").  Reports, proxy material and other information filed by
the Company can be inspected and copied at prescribed rates at the public
reference facilities maintained by the SEC at 450 5th Street, N.W. Judiciary
Plaza, Washington, D.C. 20549 and the following Regional Offices of the SEC:  7
World Trade Center, Suite 1300, New York, New York 10048 and 500 West Madison
Street, 14th Floor, Chicago, Illinois 60661-2511.  Copies of these material can
also be obtained from the Public Reference Section of the SEC at 450 5th Street,
N.W., Judiciary Plaza, Washington, D.C. 20549.


                  INCORPORATION OF CERTAIN INFORMATION BY REFERENCE

    The following documents filed by the Company with the SEC under the
Exchange Act are incorporated by reference in this Prospectus:

    1.   Annual Report on Form 10-K for the fiscal year ended October 31, 1995.

    2.   Quarterly Report on Form 10-Q for the fiscal quarter ended January 31,
         1996 and an Amendment thereto dated April 16, 1996 on Form 10 Q-A.

    3.   Proxy Statement dated February 24, 1995 for the Company's Annual
         Meeting of Stockholders.

    4.   All documents subsequently filed by the Company pursuant to Sections
         13(a), 13(c), 14 or 15(d) of the Exchange Act, prior to the
         termination of this offering will be deemed to be incorporated herein
         by reference and to be a part hereof from their respective filing
         dates.

    Any statement contained in a document incorporated or deemed to be
incorporated by reference herein shall be deemed to be modified or superseded
for purposes of this Prospectus to the extent that a statement contained herein
or in any other subsequently filed document which also is or is deemed to be
incorporated by reference herein modifies or supersedes that statement.  Any
statement so modified or superseded shall not be deemed, except as so modified
or superseded, to constitute a part of this Prospectus.

    The Company will provide without charge to each person to whom a Prospectus
Supplement is delivered, upon request, a copy of the documents incorporated by
reference in this Prospectus.  Requests should be directed to Base Ten Systems,
Inc., One Electronic Drive, Trenton, New Jersey 08169, Attention:  Edward J.
Klinsport (609) 586-7010.  Additional copies of the Prospectus are also
available from the Company or the Transfer Agent upon request.


                                 SUMMARY INFORMATION

    THE FOLLOWING SUMMARY IS QUALIFIED IN ITS ENTIRETY BY THE DETAILED
INFORMATION AND CONSOLIDATED FINANCIAL STATEMENTS INCLUDED ELSEWHERE OR
INCORPORATED BY REFERENCE IN THIS PROSPECTUS.

    Base Ten is engaged in the design and manufacture of electronic systems
employing safety critical software for defense markets and the development of
commercial applications focused on batch processing control, medical screening
and image processing software.  The Company also manufactures defense products
to specifications for prime government contractors and designs and builds
proprietary electronic systems for use in secure communications by various U.S.
government agencies.

    Specialization in extreme reliability defense products has enabled the
Company to develop expertise in the field of safety critical technology
dedicated to the prevention of performance errors.  Operations in this
environment during the last two decades have also provided experience in
developing advanced quality control procedures for


                                          1



products meeting stringent government standards as well as familiarity with
complex government regulations and agency procedures.  Over the last several
years, Base Ten has redirected resources to decrease its historical dependence
on defense contracting and has concentrated on commercial products for highly
regulated industries, relying on the same safety critical techniques developed
in its traditional businesses.  While the Company's nondefense programs involve
major potential markets, the resulting products are still primarily
developmental and may not succeed in reaching their potential.


                                     RISK FACTORS

    RISK OF RECURRING LOSSES.  The Company recognized a net loss of $875,000 or
$.13 per share in fiscal 1995 and could continue to incur losses in subsequent
periods if revenues from its nondefense software products fail to offset
declining revenues form its defense operations.  The 1995 losses resulted from
reduction in defense related sales and an increase in expenses associated with
the development and introduction of nondefense products by Base Ten's Medical
Technology Division.  The Company's commercial development of its manufacturing
execution, medical screening and ultrasound image archiving software products
have been internally funded and could be adversely affected by delays in the
development cycle, competition and changing technology.

    RISKS ASSOCIATED WITH DEPENDENCE ON MAJOR CONTRACTS.  Base Ten's defense
operations have historically been dependent on a limited number of customers or
contracts.  The Company  primary revenue sources during fiscal 1995, 1994 and
1993 were defense related programs with the United States military and other
agencies or contractors, accounting for 40%, 28% and 68% of revenues,
respectively.  The Company has also remained dependent on the sale of weapons
control systems for the West German and Italian versions of the Tornado
aircraft, accounting for 36% of revenues in fiscal 1995 and 1994 and 17% of
fiscal 1993 revenues.  Profit margins for these programs are limited by strict
government procedures, and all aspects of the Company's participation in these
markets are characterized by intense competition.  Base Ten's investment of
funds in product development has not always resulted in sales.  Any termination
of the Company's major contracts or loss of its primary customers in this market
would have a material adverse impact on its financial condition.

    RISKS ASSOCIATED WITH CHANGE IN BUSINESS DIRECTION.  In response to sharp
declines in sales and profitability resulting from significant reductions in
military defense expenditures beginning in 1990, Base Ten implemented a plan for
reducing fixed costs and redeploying its resources to development projects that
are subject to all of the risks inherent in the commercialization of new
products for nondefense markets in which the Company is not an established
participant.  The Company has been required to significantly increase its
technical and marketing staffs to accommodate anticipated growth in these fields
without any assurance of achieving that growth.  The developmental nature of
these products makes their ultimate success in the marketplace uncertain.

    RISKS OF DELAYS IN OBTAINING REGULATORY APPROVALS FOR NEW PRODUCTS.
Because the Company has concentrated  on products that draw upon its electronic,
software and systems engineering capabilities in safety critical, highly
regulated environments, many of its new products are subject to regulatory
approval procedures that increase development costs and can substantially delay
commercialization efforts.  Base Ten's medical screening programs involve
noninvasive testing procedures but are nevertheless treated by the Food and Drug
Administration (the  FDA ) as a medical device under guidelines introduced in
1991, requiring FDA clearance prior to sales in the United States.  The Company
s first medical screening software program was submitted to the FDA in August
1992 and was initially subjected to review under a premarket approval
application supported by prospective clinical data before an Advisory Panel
convened by the FDA denied approval on the grounds that the product should not
be classified as a medical device.  The FDA subsequently reclassified the
software as a Class 1 Tier 3 medical device requiring only a 510(k) premarket
notification and granted Base Ten permission to market the device beginning in
September 1995.  Although the basic software used in this device can be applied
to a wide variety of medical screening programs, the Company has postponed
further development efforts for this product line pending implementation of a
more favorable regulatory environment.  Uncertainties in the domestic regulatory
structure and delays inherent in approval procedures could deter or postpone
other commercial development efforts by the Company.

    RISK OF INADEQUATE FINANCIAL RESOURCES.  The Company has financed its
development efforts to date from equity capital and retained earnings, depleting
its cash and cash equivalents to $3.6 million at the end of fiscal 1995.


                                          2



In view of its limited financial resources, Base Ten will be unable to continue
pursuing its development objectives at the desired pace and scope without
additional financing or increased sales of its new products.  Funds generated
from operations of the Medical Technology Division to date have been
substantially less than the development and marketing costs for these products.
In the absence of accelerated sales by the Medical Technology Division, the
Company could be required to raise additional equity capital or incur debt to
finance future development activities.  The issuance of additional equity could
be dilutive to existing stockholders, and the alternative of financing
development through borrowings could weaken the Company s financial condition.

    RISK OF INADEQUATE MARKETING RESOURCES.  Success in the technological
development and refinement of the Company s new products will not guarantee
profitable sales without substantial marketing resources that may be unavailable
to Base Ten.  The Company's limited exposure to healthcare, pharmaceutical
manufacturing and other relevant commercial markets along with financial
constraints could impair its ability to penetrate those markets with sufficient
speed to fully capitalize on its technological lead time.  The Company is
dependent on strategic alliances and OEM relationships to facilitate marketing
arrangements for its new products in the EEC and is primarily dependent on its
own limited marketing resources for penetrating domestic markets.

    INTENSELY COMPETITIVE NATURE OF THE COMPANY'S BUSINESS.  Base Ten competes
in both defense and commercial sectors with a number of businesses that have
substantially greater financial, technical, manufacturing and marketing
resources.  In the defense sector, the Company competes with established U.S.
and foreign manufacturers of weapons control and similar equipment, many of whom
are able to offer a broader product base.  In the secure communications market,
competitors include established manufacturers that have greater experience as
well as product diversification.  In the markets for its manufacturing
execution, medical screening and ultrasound image archiving software, Base Ten
believes it competes with many small and several large established firms with
assets and resources substantially greater than those available to the Company.

    RISK OF TECHNOLOGICAL OBSOLESCENCE.  The industries in which the Company
competes are characterized by rapid technological changes.  Accordingly,
products using different technologies could be introduced before market
acceptance is achieved for any of Base Ten s new products.  Historically, Base
Ten has experienced time lags of up to three years between commencement of
marketing activities through the completion of field trials and ultimate sales
of its military products.  A similar time lag was experienced in securing
regulatory approval from the FDA for the Company's first medical screening
product.  Similar or longer delays could be experienced for other products,
during the course of which Base Ten could face the risk of the products
technological obsolescence.

    RISKS FROM DEPENDENCE ON SUBCONTRACTORS.  The Company s manufacturing
operations primarily involve the assembly of final products from components and
sub-assemblies supplied by other manufacturers.  Base Ten has single sources of
supply for certain sub-assemblies and integrated circuits manufactured to its
specifications.  The Company's efforts to maintain an inventory of material and
components to cover foreseeable production requirements would not protect it
against production delays and increased costs if a single source were unable to
support its needs.  Delays in the Company's manufacturing output could adversely
affect its contractual performance and cash flow.

    RISKS ASSOCIATED WITH DEPENDENCE ON KEY PERSONNEL.  The Company's success
will continue to be dependent  to a large extent upon its ability to retain the
services of its executive officers and technical staff.  To reduce costs, Base
Ten has curtailed salary increases from time to time and suspended contributions
to its 401(k) plan.  Current compensation and benefit levels could contribute to
the loss of any key personnel or reduced productivity, either of which could
have a materially adverse affect on the Company.

    FOREIGN TRADE AND CURRENCY EXCHANGE RELATED RISKS.  A portion of the
Company's revenues is derived from foreign customers and is subject to
disruption by political and economic conditions abroad.  Currency exchange
fluctuations could also affect the Company by increasing the price of its
products to foreign customers or decreasing the cost of competing products
abroad.

    NO DIVIDENDS.  Base Ten has not paid dividends on its Common Stock since
1985 and presently intends to retain any future earnings for reinvestment in its
business.  Accordingly, the Company does not anticipate paying any dividends in
the foreseeable future.


                                          3



    CONTROL BY HOLDERS OF CLASS B COMMON STOCK.  Holders of the Company's Class
B Common Stock, of which 48.91% is owned on a fully diluted basis by management,
are entitled to elect 75% of the members of Base Ten's board of directors (the
Board ).  In addition, holders of Class B Common Stock receive one vote per
share held, compared to one-tenth (1/10th) of one vote per share held for Class
A Common Stock, on all matters other than the election of directors submitted to
the Company's shareholders, entitling holders of Class B Common Stock to 39% of
the Company s combined voting power on those matters.  Accordingly, holders of
the Class B Common Stock are able to control the election of a majority of the
members of the Board and to substantially influence all other aspects of
corporate governance.

    DEPENDENCE ON CONTINUATION OF SECURITY CLEARANCES.  The Company relies on
the continuance of its security clearances from agencies of the United States
government and from NATO for its defense products.  If Base Ten experienced any
material deficiencies in the manner or method of complying with prescribed
security regulations, any resulting loss of its security clearances would have
an immediate and adverse affect on the Company's business.

                             DESCRIPTION OF CAPITAL STOCK

GENERAL.

    The authorized capital stock of Base Ten consists of 22,000,000 shares of
Class A Common Stock, 2,000,000 shares of Class B Common Stock and 1,000,000
shares of Preferred Stock, all of which have a par value of $1.00 per share.

COMMON STOCK

    DIVIDENDS.  Both classes of Base Ten's Common Stock have identical cash and
property dividend rights except that no cash or property dividend may be paid on
the Class B Common Stock unless a dividend at least equal in amount is paid
concurrently on the Class A Common Stock.  Cash or property dividends can be
declared and paid on the Class A Common Stock without being declared and paid on
the Class B Common Stock.

    If a distribution is paid in shares of Class A Common Stock or Class B
Common Stock, the distribution may be paid only as follows:  (i) shares of Class
A Common Stock may be paid to holders of shares of Class A Common Stock and
shares of Class B Common Stock may be paid to holders of shares of Class B
Common Stock, and (ii) the same number of shares shall be paid in respect of
each outstanding share of Class A Common Stock or Class B Common Stock.  Base
Ten may not subdivide or combine shares of either class without at the same time
proportionately subdividing or combining shares of the other class.

    VOTING RIGHTS.  Holders of Class A Common Stock are entitled to elect 25%
of the members of the Board of Directors (rounded to the next highest whole
number) so long as the number of outstanding shares of Class A Common Stock is
at least 10% of the number of outstanding shares of both classes.  Currently,
the holders of Class A Common Stock are entitled, as a class, to elect two
directors of Base Ten, and the holders of the Class B Common Stock are entitled,
as a class, to elect the remaining three directors.  As a result of this
provision, the holders of a majority of the Class B Common Stock can and will
continue to be able to elect a majority of the directors and thereby control
Base Ten, regardless of the number of shares of Class B Common Stock outstanding
from time to time.  Directors may be removed, only for cause, by the holders of
the class of common stock which elected them.

    Except for the election or removal of directors as described above and
except for class votes as required by law or Base Ten's Restated Certificate of
Incorporation, holders of both classes of common stock vote or consent as a
single class on all matters, with each share of Class A Common Stock having one-
tenth vote per share and each share of Class B Common Stock having one vote per
share.

    The outstanding shares of the Class A Common Stock currently represents
approximately 92% of the total number of shares of both classes outstanding.  If
the number of outstanding shares of Class A Common Stock should becomes less
than 10% of the total number of shares of both classes of common stock
outstanding, the holders of Class A Common Stock would not have the right to
elect 25% of the Board of Directors, but would have one-tenth vote per share for
all directors, and the holders of Class B Common Stock would have one vote per
share for all directors.


                                          4



    CONVERSION.  At the option of the holder of record, each share of Class B
Common Stock is convertible at any time into one share of Class A Common Stock.
Conversion of a significant number of shares of Class B Common Stock into Class
A Common Stock could put control of the Board of Directors into the hands of the
holders of a relatively small equity interest in Base Ten who would continue to
hold the Class B Common Stock.  The Class A Common Stock is not convertible.

    OTHER RIGHTS.  Shareholders of the Base Ten have no preemptive or other
rights to subscribe for additional shares.  On liquidation, dissolution or
winding up of Base Ten, all shareholders, regardless of class, are entitled to
share ratably in any assets available for distribution.  No shares of either
class are subject to redemption.  All outstanding shares are fully paid and non-
assessable.

    TRANSFER AGENT.  The transfer agent and registrar for shares of the Class A
Common Stock and Class B Common Stock is American Stock Transfer & Trust
Company, 40 Wall Street, New York, New York 10005.

PREFERRED STOCK

    No shares of Preferred Stock have been issued.  Base Ten's Board of
Directors is empowered to fix the designations, powers, preferences and
relative, participating, optional or other special rights of the Preferred Stock
and the qualifications, limitations or restrictions of those preferences or
rights.  The voting rights of the Class B Common Stock described above are
subject to voting rights that may be granted in connection with the creation of
any series of Preferred Stock.  However, no issue of Preferred Stock may change
the ratio of one-tenth of a vote for each share of Class A Common Stock to one
vote for each share of Class B Common Stock described above.


                                 SELLING STOCKHOLDERS

    The following table sets forth (i) the name of each Selling Stockholder,
(ii) to the best of the Company's knowledge, the total number of shares of Class
A Common Stock owned beneficially by each Selling Stockholder as of the date of
this Prospectus, (iii) the number of Shares to be offered for the account of
each Selling Stockholder in this offering and (iv) to the best of the Company's
knowledge, the number of shares of Class A Common Stock to be owned by each
Selling Stockholder after giving effect to this offering.




                                                                            NUMBER OF
                                                                            SHARES OF
                                               NUMBER OF     NUMBER OF     STOCK TO BE
                                               SHARES OF    SHARES TO BE   OWNED AFTER
NAME                                          STOCK OWNED     OFFERED      THE OFFERING
- ----                                          -----------   ------------   ------------
                                                                  
Alexander M. Adelson                             369,416      161,000          208,416
Bruce D. Cowen                                   606,250      175,000          431,250
Donald M. Daniels                                 10,000       10,000                0
Alan S. Poole                                     10,000       10,000                0
Daniel Tierney                                    15,000       15,000                0
Pharma Overseas, Ltd.                             30,000       30,000                0
Strategic Growth International, Inc.             150,000       50,000          100,000
                                              ----------    ---------      -----------
Total                                          1,190,666      451,000          739,666
                                              ----------    ---------      -----------
                                              ----------    ---------      -----------


    The information set forth in the foregoing table was provided to the
Company by the Selling Stockholders.  None of the Selling Stockholders has had
any position or other material relationship with the Company or its affiliates
during the past three years, except that Messers. Adelson and Daniels have
served as directors of Base Ten since 1992, Mr. Poole has served as a director
of Base Ten since 1994, Mr. Cowen has served as a consultant to the Company
since 1991, Mr. Tierney is an officer of Clonmel Health Care, Ltd., an Irish
pharmaceutical manufacturer that has been a customer of Base Ten during the last
three years, and Strategic Growth International, Inc. has provided public
relations services to the Company during that period.


                                          5



    All of the Shares being offered hereunder by the Selling Stockholders are
issuable upon exercise of warrants or options issued by Base Ten to the Selling
Stockholders.  The Company agreed to register the Shares for the accounts of the
Selling Stockholders and has filed with the Securities and Exchange Commission
under the Securities Act a Registration Statement on Form S-3 of which this
Prospectus is a part, covering the resale of the Shares from time to time.


                                 PLAN OF DISTRIBUTION

    The Shares being offered hereunder by the Selling Stockholders will be
offered from time to time in open market transactions, negotiated transactions,
principal transactions or by a combination of these methods of sale.  The Shares
may be offered at market prices prevailing at the time of sale, at prices
related to the prevailing market prices or at negotiated prices.  The Selling
Stockholders may effect these transactions by selling Shares to or thorugh
broker-dealers.  Broker-dealers may receive compensation in the form of
discounts, concessions or commissions from Selling Stockholders or purchasers
for whom the broker-dealers may act as agent or to whom they sell as principal
or both.  Compensation paid to a particular broker-dealer might be in excess of
customary commissions.  Selling Stockholders and broker-dealers participating in
the sale of Shares may be deemed to be underwriters, and any profit on the sale
of Shares or compensation received by them may be deemed to be underwriting
compensation under the Securities Act.

    The Company has agreed with the Selling Stockholders, among other things,
(i) to bear all expenses (other than underwriting discounts and selling
commissions, and fees and expenses of counsel and other advisers to the Selling
Stockholders) in connection with the registration and sale of the Shares being
offered by them and (ii) to indemnify the Selling Stockholders against certain
liabilities, including liabilities under the Securities Act, as underwriters or
otherwise.


                                          6